Orchestra BioMed Holdings Inc. (OBIO) - Net Assets
Based on the latest financial reports, Orchestra BioMed Holdings Inc. (OBIO) has net assets worth $43.74 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($104.81 Million) and total liabilities ($61.07 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check OBIO asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $43.74 Million |
| % of Total Assets | 41.73% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 40.54 |
Orchestra BioMed Holdings Inc. - Net Assets Trend (2020–2024)
This chart illustrates how Orchestra BioMed Holdings Inc.'s net assets have evolved over time, based on quarterly financial data. Also explore how large is Orchestra BioMed Holdings Inc.'s balance sheet for the complete picture of this company's asset base.
Annual Net Assets for Orchestra BioMed Holdings Inc. (2020–2024)
The table below shows the annual net assets of Orchestra BioMed Holdings Inc. from 2020 to 2024. For live valuation and market cap data, see Orchestra BioMed Holdings Inc. market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $32.96 Million | -51.56% |
| 2023-12-31 | $68.04 Million | +29.52% |
| 2022-12-31 | $52.53 Million | +173.75% |
| 2021-12-31 | $-71.23 Million | -46.74% |
| 2020-12-31 | $-48.54 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Orchestra BioMed Holdings Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 16676600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $4.00K | 0.01% |
| Other Comprehensive Income | $52.00K | 0.16% |
| Other Components | $342.78 Million | 1040.05% |
| Total Equity | $32.96 Million | 100.00% |
Orchestra BioMed Holdings Inc. Competitors by Market Cap
The table below lists competitors of Orchestra BioMed Holdings Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
UJU Electronics Co. Ltd
KQ:065680
|
$216.27 Million |
|
DAEA TI Co. Ltd
KQ:045390
|
$216.31 Million |
|
PTC India Financial Services Limited
NSE:PFS
|
$216.58 Million |
|
Akmerkez Gayrimenkul Yatirim Ortakligi AS
IS:AKMGY
|
$216.58 Million |
|
Re Max Holding
NYSE:RMAX
|
$216.21 Million |
|
CARGO Therapeutics, Inc. Common Stock
NASDAQ:CRGX
|
$216.19 Million |
|
Creditwest Faktoring AS
IS:CRDFA
|
$216.09 Million |
|
New Era Energy & Digital, Inc.
NASDAQ:NUAI
|
$215.93 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Orchestra BioMed Holdings Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 68,043,000 to 32,958,000, a change of -35,085,000 (-51.6%).
- Net loss of 61,024,000 reduced equity.
- New share issuances of 15,035,000 increased equity.
- Other comprehensive income increased equity by 62,000.
- Other factors increased equity by 10,842,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-61.02 Million | -185.16% |
| Share Issuances | $15.04 Million | +45.62% |
| Other Comprehensive Income | $62.00K | +0.19% |
| Other Changes | $10.84 Million | +32.9% |
| Total Change | $- | -51.56% |
Book Value vs Market Value Analysis
This analysis compares Orchestra BioMed Holdings Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.44x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $-2.37 | $3.97 | x |
| 2021-12-31 | $-3.48 | $3.97 | x |
| 2022-12-31 | $2.06 | $3.97 | x |
| 2023-12-31 | $2.05 | $3.97 | x |
| 2024-12-31 | $0.90 | $3.97 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Orchestra BioMed Holdings Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -185.16%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2313.27%
- • Asset Turnover: 0.03x
- • Equity Multiplier: 2.31x
- Recent ROE (-185.16%) is below the historical average (-64.26%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 0.00% | -374.45% | 0.15x | 0.00x | $-16.50 Million |
| 2021 | 0.00% | 0.00% | -0.06x | 0.00x | $-15.89 Million |
| 2022 | -63.97% | -951.26% | 0.04x | 1.82x | $-38.86 Million |
| 2023 | -72.19% | -1779.71% | 0.03x | 1.40x | $-55.92 Million |
| 2024 | -185.16% | -2313.27% | 0.03x | 2.31x | $-64.32 Million |
Industry Comparison
This section compares Orchestra BioMed Holdings Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Orchestra BioMed Holdings Inc. (OBIO) | $43.74 Million | 0.00% | 1.40x | $216.26 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develop… Read more